Cosyntropin as a diagnostic agent in the screening of patients for adrenocortical insufficiency

David D Hamilton
Bryan A Cotton

Department of Surgery, The University of Texas Health Science Center, Houston, TX, USA

Abstract: Adrenocortical insufficiency occurs when there is inadequate release of cortisol from the adrenal cortex. Disturbances of the hypothalamic–pituitary–adrenal axis are common following trauma, surgical stress, and critical illness. While this is often a protective mechanism, these responses may become "uncoupled" or maladaptive resulting in an exacerbation of organ failure and higher mortality rates. In these clinical settings, the patient presents with a persistent systemic inflammation state, a hyperdynamic cardiovascular response, and vasopressor dependent shock. As such, the occurrence of adrenal insufficiency in the setting of critical illness is most appropriately termed critical illness-related corticosteroid insufficiency. In these settings, recent data suggests that these patients may benefit from a short course of low-dose steroid replacement therapy. Cosyntropin, a synthetic derivative of adrenocorticotropic hormone, is being used with increased frequency in the evaluation and diagnosis of adrenocortical insufficiency in this patient population. A random cortisol level is checked before a 250-µg injection of cosyntropin and then 30–60 minutes later. The cortisol levels and response to cosyntropin may be interpreted to identify an insufficient adrenal response. Of note, the setting of critical illness can greatly affect the cosyntropin test sensitivity on identifying adrenal insufficiency. Changes in the stress response during critical illness combined with the resuscitation and management of these patients greatly disturbs serum protein levels, especially those of albumin and transcortin. Common intensive care unit (ICU) diagnoses such as sepsis and malnutrition can increase baseline levels and blunt the cortisol response to cosyntropin stimulation, respectively. As well, numerous pharmacological agents routinely used in the ICU have been shown to interfere with cortisol levels and cosyntropin responsiveness. While steroids have a place in the ICU, specific dosing and length of administration remain inconsistent

Keywords: critical illness, ACTH, cosyntropin, adrenal insufficiency

Adrenocortical insufficiency

Adrenocortical insufficiency occurs when there is inadequate release of cortisol from the adrenal cortex. The incidence rate of adrenal insufficiency is approximately five cases per million people per year with a prevalence of 35 to 60 cases per million in Western countries.1,2 Primary adrenal insufficiency is due to an impairment of the adrenal glands, while secondary adrenal insufficiency is caused by impairment of the pituitary gland, tertiary insufficiency is due to hypothalamic dysfunction. Intrinsic adrenal disease arises from three general mechanisms: congenital adrenal hypoplasia, defective steroid synthesis, and adrenal destruction (from autoimmune causes, infection, adrenal replacement by metastatic tumor, and adrenal hemorrhage as in Waterhouse–Friderichsen syndrome) (Table 1).
Cosyntropin: pharmacology and pharmacokinetics

Cosyntropin is a synthetic derivative of adrenocorticotropic hormone (ACTH) that is used in the evaluation and diagnosis of patients with adrenocortical insufficiency. ACTH is a naturally occurring peptide hormone that is secreted by the anterior pituitary to act on the cells of the adrenal cortex to

Table 1 Causes of adrenal insufficiency

<table>
<thead>
<tr>
<th>Primary</th>
<th>Secondary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune adenositis</td>
<td>Chronic steroid use</td>
</tr>
<tr>
<td>Metastatic carcinoma</td>
<td>Pituitary or metastatic tumor</td>
</tr>
<tr>
<td>Infection (HIV, Tb, Fungal)</td>
<td>Pituitary surgery or radiation</td>
</tr>
<tr>
<td>Hemorrhage/infarction (disseminated intravascular coagulation, meningococemia, anticoagulation, heparin-induced thrombocytopenia)</td>
<td>Empty-sella syndrome</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Craniopharyngioma</td>
</tr>
<tr>
<td>Drugs (ketoconazole, etomidate, mitotane, metyrapone)</td>
<td>Infusion (HIV, sarcoidosis, histiocytosis)</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Head trauma</td>
</tr>
<tr>
<td>Genetic (adrenoleukodystrophy, autoimmune polyglandular disease)</td>
<td>Post-partum pituitary necrosis (Sheehan's syndrome)</td>
</tr>
</tbody>
</table>

Abbreviations: HIV, human immunodeficiency virus; Tb, tuberculosis.
increase secretion of glucocorticoids, mineralocorticoids, and sex steroids. Cosyntropin is an open chain polypeptide containing the first 24 of the 39 amino acids of natural ACTH. It stimulates adrenal activity to the same extent of natural ACTH. The biologic activity of ACTH resides in the N-terminal portion of the molecule and the 1–20 amino acid residue is the minimal sequence retaining full activity. Progressive shortening of the chain beyond 20 amino acid residues results in partial or complete loss of activity. For example, the decrement from 20 to 19 results in a 70% loss of potency. Cosyntropin is sometimes referred to outside of the United States as tetracosactide.

The pharmacologic profile of cosyntropin is similar to that of purified natural ACTH. A single dose of 0.25 mg of cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. The half-life of cortisol is in the range of 70 to 120 minutes. However, the half-life for cosyntropin is only 15 minutes. Administration is by intravenous or intramuscular injection and a rise in cortisol should generally be seen around 30 minutes after administration. Plasma cortisol levels usually peak about 45 to 60 minutes after injection and a normal response is an approximately doubling of the basal plasma cortisol value. A number of other agents may interfere with cosyntropin function and subsequent response. These include metyrapone, etomidate, ketoconazole, megesterol, and mitotane to name a few. In addition, agents such as rifampin and phenytoin may increase cortisol metabolism.

Cosyntropin has also been used to eliminate fluctuations in aldosterone levels during adrenal venous sampling for aldosteronoma localization. Blood is obtained from the right and left adrenal veins, the inferior vena cava, or the peripheral veins. The key diagnostic feature in the case of an adenoma is unilateral elevation of aldosterone, with suppression of contralateral aldosterone. Levels drawn from the inferior vena cava or peripheral samples should be higher than from the contralateral suppressed gland.

Side effects of cosyntropin include nausea, anxiety, sweating, dizziness, itchy skin, redness and or swelling at injection site, palpitations, and facial flushing. Rarely seen side effects include fainting, headache, blurred vision, severe swelling, severe dizziness, trouble breathing, or an irregular heartbeat. A rare hypersensitivity reaction usually associated with a pre-existing allergic disease or prior ACTH allergy is possible. Bradycardia, tachycardia, hypertension, peripheral edema have all been reported after administration of cosyntropin. Additionally, cosyntropin may accentuate the electrolyte loss associated with diuretic therapy. Cosyntropin is pregnancy Category C; meaning it is not known if cosyntropin can cause fetal harm or affect reproduction capacity. Administration to a pregnant woman should only be if clearly needed. Caution should also be exercised when cosyntropin is administered to a woman who is breastfeeding. The extra-adrenal effects, which natural ACTH and cosyntropin have in common, include increased melanotropic activity, increased growth hormone secretion, and lipogenesis. These are considered to be without physiological or clinical significance.

**Table 2 American College of Critical Care Medicine’s task force guidelines for diagnosis and management of adrenal insufficiency in critical illness**

**Diagnosis of adrenal insufficiency**
1. Adrenal insufficiency is best diagnosed by a change in cortisol (after 250 µg cosyntropin) of <9 µg/dL or a random total cortisol of <10 µg/dL.
2. Free cortisol measurements cannot be recommended for routine use at this time.
3. ACTH stimulation testing should not be used to identify those patients with septic shock or ARDS who should receive glucocorticoid therapy.

**Treatment of adrenal insufficiency**
1. Prednisone should be considered in patients with septic shock who have responded poorly to fluid resuscitation and vasopressor agents.
2. Moderate-dose glucocorticoid therapy should be considered in patients with early severe ARDS (PaO2/FIO2 of <200) and before day 14 in patients with unresolved ARDS.
3. Patients with septic shock should be treated for seven days before tapering, while patients with early ARDS should be treated for 14 days before tapering.


**Abbreviations:** ACTH, adrenocorticotropic hormone; ARDS, acute respiratory distress syndrome.
pretest probability is sufficiently high. The operating characteristics of the 250 µg and 1 µg cosyntropin tests are similar.\textsuperscript{20}

The low-dose ACTH stimulation test (1 µg) has been shown to be more sensitive and specific than the high-dose test (250 µg), however; the high-dose test is preferred since the low-dose test has not been validated.\textsuperscript{20,21} The test has a reported specificity of 95%, with sensitivities of 97%, 57%, and 61% for primary adrenal insufficiency (250 µg cosyntropin test), secondary adrenal insufficiency (250 µg cosyntropin test), and secondary adrenal insufficiency (1 µg cosyntropin test), respectively. Therefore the cosyntropin stimulation test is helpful for ruling in secondary AI, but not for ruling it out.\textsuperscript{20} In unstressed subjects, adrenal insufficiency is confirmed when the baseline cortisol is less than 3 µg/dL or the 250 µg ACTH-stimulated cortisol is less than 18–20 µg/dL.\textsuperscript{2,20,22} Alternatively suspected AI can be diagnosed with a post-cosyntropin level of at least 20 µg/dL for primary AI and at least 25–30 µg/dL for secondary AI.

The diagnosis and treatment of adrenal insufficiency in critical illness has been the subject of controversy for over 30 years. In 1977, Sibbald and colleagues reported that almost 20% of patients in septic shock have subnormal responses to ACTH administration.\textsuperscript{23} Since that time, however, the diagnosis (and even the existence) of CIRCI has been highly debated. Specifically, tumor necrosis factor (TNF) alfa and interleukin-1 (IL-1) have been implicated as inflammatory mediators in the reversible dysfunction of the HPA axis during critical illness. TNF-α likely impairs corticotropin-releasing hormone stimulated ACTH release, and a number of clinical studies have reported inappropriately low ACTH levels in patients with severe sepsis.\textsuperscript{24,25} The incidence of CIRCI varies widely from 10% to 71% depending of the definition used.\textsuperscript{26} However, making a clinical diagnosis is difficult in critically ill patients because systemic vascular resistance, cardiac output, and pulmonary capillary wedge pressure can be low, normal, or even high.\textsuperscript{27}

While multiple tests have been developed to diagnose CIRCI, the most commonly used test is the ACTH stimulation test. In this setting, random cortisol levels are checked before a 250 µg injection of cosyntropin and then 30–60 minutes later. The cortisol levels and response to cosyntropin may be interpreted to identify an insufficient adrenal response. Currently, either a random cortisol of less than 10 to 15 µg/dL or changes in cortisol of less than 9 µg/dL are the best tests for the diagnosis of adrenal insufficiency. Both values have an acceptably high specificity but low sensitivity.\textsuperscript{28} Several authors have demonstrated that nonsurvivors generally have higher baseline cortisol levels and a lower cortisol response to ACTH.\textsuperscript{26,29} However, free serum cortisol levels can be normal in critically ill patients who have low total serum cortisol; most likely as a result of a reduction in binding proteins during times of injury, stress and critical illness.\textsuperscript{30} Hamrahian and colleagues investigated total and free cortisol as well as cosyntropin stimulation responses in healthy volunteers and patients with sepsis. The authors found that while total cortisol levels were often consistent with adrenal insufficiency, free cortisol levels (not impacted by hypoproteinemia) demonstrated that these same patients had normal adrenal function. In patients with severe hypoproteinemia, adrenal insufficiency may be best defined by a baseline serum free cortisol concentration less than 2.0 µg/dL or ACTH-stimulated free cortisol concentrations less than 3.1 µg/dL.

In the 1990’s, several papers indicated a potential benefit of a brief course of corticosteroid therapy in critically ill patients (specifically those with vasopressor-dependent septic shock) who failed an ACTH stimulation test.\textsuperscript{8,31,32} However, in 2008, the results of the multicenter, multinational CORTICUS trial demonstrated that hydrocortisone cannot be recommended as general adjuvant therapy for vasopressor responsive septic shock.\textsuperscript{33} As well, the authors concluded that corticotropin testing could not be recommended to determine which patients should receive hydrocortisone therapy. In that trial, hydrocortisone did not improve survival or reverse shock, in patients with septic shock, either overall or in patients who did not respond to cosyntropin. It was noted however that in responders, the shock was reversed much faster.\textsuperscript{33}

Of note is that the setting of critical illness can in, and of itself, greatly affect the cosyntropin test sensitivity in identifying adrenal insufficiency. The stress of critical illness and injury can greatly increase cortisol production while increasing glucocorticoid resistance.\textsuperscript{28} The changes in the stress response during critical illness combined with the resuscitation and management of these patients greatly disturbs serum protein levels, especially those of albumin and transcortin. With lower levels of these binding proteins, baseline cortisol and post-stimulation levels are generally lower than in similar states where albumin levels are normal. Complicating this, frequent intensive care unit (ICU) diagnoses such as sepsis and malnutrition can increase baseline levels and blunt the cortisol response to cosyntropin stimulation, respectively.

Further complicating the diagnosis of CIRCI in the ICU setting are the numerous commonly used agents that have been shown to interfere (in varying degrees) with cortisol levels and cosyntropin responsiveness. Several pharmacologic agents frequently used in the severely injured and
critically ill populations have been shown to impair adrenal function and steroidogenesis. Propofol impairs adrenal steroidogenesis, while agents such as midazolam, morphine, and fentanyl have been shown to blunt the HPA axis, thereby interfering with corticosteroid metabolism. Etomidate is an imidazole derivative frequently used as an induction agent for rapid sequence intubation. In critically ill and injured patients, etomidate has gained increasing popularity for its rapid onset of action, cardiovascular stability, and limited respiratory depression. However, it is well established that adrenal suppression (via inhibition of 11-b hydroxylase), has brought the use of etomidate into question. In fact, among the major risk factors (coagulopathy, mechanical ventilation, hemorrhagic shock, vasopressor use, and septic shock) evaluated by Cotton and colleagues, etomidate use was the only modifiable risk factor identified.

A single dose of etomidate has been demonstrated to inhibit cortisol production for up to 48 hours. Exposure to etomidate is a risk factor for the development of CIRCI in critically injured patients, and alternative drugs should be used when possible. In a reanalysis of a double blind clinical trial of 299 patients with septic shock randomized to receive placebo or corticosteroids, 77 (26%) patients received etomidate. Of these, 94% did not respond well to cosyntropin stimulation and the blockade of steroidogenesis lasted around 72 hours. More importantly, mortality was different between etomidate treated patients randomized to placebo (76%) and those randomized to corticosteroids (55%). This statistically significant absolute risk reduction of 21% translates into a number needed to treat of five patients.

Clearly steroids have a place in the ICU. However, their dosing and length of administration remain inconsistent. The use of extended course, stress-dose corticosteroids has been evaluated in ten randomized controlled clinical trials in critically ill patients with sepsis and acute respiratory distress syndrome (ARDS). This dosing strategy has been reported to be associated with a reduction in mortality, more rapid weaning of vasopressor agents, decreased ICU length of stay, and an increase in ventilator-free days in ARDS. Randomized controlled trials evaluating the outcomes of high-dose, short course corticosteroid treatment in ARDS and sepsis have been unable to show improved outcomes, and there was a higher incidence of complications in the patients who received high-dose corticosteroids. Treatment with moderate-dose corticosteroids is recommended in patients with septic shock who have responded poorly to volume resuscitation and vasopressor agents. In patients with early severe ARDS and unresolving ARDS, treatment with moderate dose glucocorticoids should be considered before day 14.

Although previous studies have suggested that the treatment of patients with septic shock should be based on the results of a cosyntropin stimulation test, the limitations of this test in diagnosing adrenal insufficiency in the setting of critical illness, combined with the benefit of corticosteroids in both responders and nonresponders suggest that this test should not be used to select patients likely to derive benefit from corticosteroids. In a recent critical appraisal of how to approach this patients population when relative or occult adrenal insufficiency is suspected, Marik recommends initiating treatment with stress-doses of corticosteroids in patients with vasopressor-dependent septic shock within 12 hours of presentation. He also recommends doing so without stimulation testing but rather based on clinical suspicion or random free cortisol levels.

Conclusion
Cosyntropin is a synthetic derivative of ACTH that is used in the evaluation and diagnosis of patients with adrenocortical insufficiency. Cosyntropin stimulation testing remains the cornerstone of diagnosing both primary and secondary adrenal insufficiency. While both the low-dose (1 µg) and high-dose versions (250 µg) have been shown to diagnose adrenal insufficiency, the 1 µg dose has been shown to be more sensitive and specific. However, its poor specificity in secondary adrenal insufficiency limits its use in definitively ruling out this diagnosis. In the critically ill patient population presenting with CIRCI, based on currently available data, stimulation testing of adrenal function should not be routinely performed. Steroid therapy should be started presumptively in hemodynamically unstable patients while those who are stable may await random cortisol level results.

Disclosure
The authors report no conflicts of interest relevant to this research.

References